AKN-028 is a novel tyrosine kinase inhibitor with preclinical activity in acute myeloid leukemia (AML), presently undergoing investigation in a phase I/II study. It is a potent inhibitor of the FMS-like kinase 3 (FLT3) but shows in vitro activity in a wide range of AML samples. In the present study, we have characterized the effects of AKN-028 on AML cells in more detail. AKN-028 induced a dose...

Aberrantly expressed tyrosine kinases have emerged as promising targets for drug development in acute myeloid leukemia (AML). We report that AKN-028, a novel tyrosine kinase inhibitor (TKI), is a potent FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor (IC(50)=6 nM), causing dose-dependent inhibition of FLT3 autophosphorylation. Inhibition of KIT autophosphorylation was shown in a human mega...

Eriksson, A. 2012. Studies of New Signal Transduction Modulators in Acute Myeloid Leukemia. Acta Universitatis Upsaliensis. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 823. 61 pp. Uppsala. ISBN 978-91-554-8495-8. Acute myeloid leukemia (AML) is a life-threatening malignant disorder with dismal prognosis. AML is characterized by frequent genetic changes ...

Consumption of the MCTD also resulted in significant elevation of blood β-hydroxybutyrate concentrations in comparison with placebo diet (0·071 (SD 0·035) v. 0·053 (SD 0·028) mmol/l, P = 0·028).’ Results ‘There was a significant increase in blood concentrations of BHB when dogs were fed the MCTD (0·071 (SD 0·035) mmol/l) in comparison with the placebo diet (0·053 (SD 0·028) mmol/l, P = 0·028).’...

TSO Shops 123 Kingsway, London,WC2B 6PQ 020 7242 6393 Fax 020 7242 6394 68-69 Bull Street, Birmingham B4 6AD 0121 236 9696 Fax 0121 236 9699 9-21 Princess Street, Manchester M60 8AS 0161 834 7201 Fax 0161 833 0634 16 Arthur Street, Belfast BT1 4GD 028 9023 8451 Fax 028 9023 5401 18-19 High Street, Cardiff CF10 1PT 029 2039 5548 Fax 029 2038 4347 71 Lothian Road, Edinburgh EH3 9AZ 0870 606 5566 ...

(51) Int. Cl. B64C 3/38 (2006.01) B64C 31/02 (2006.01) B64C 39/02 (2006.01) B64C 3/42 (2006.01) G05D I/10 (2006.01) (52) U.S. CI. CPC ................. B64C39/028 (2013.01); B64C3/42 (2013.01); G05D I/105 (2013.01); YO2T50/145 (2013.01) (58) Field of Classification Search CPC ............ B64C 3/38: B64C 3/385, B64C 3/42; B64C3/56; B64C 31/02; B64C39/028; A63H 27/08: A63H 27/007; A63H 27/00; Y0...

From March 1997 through November 1997, 8 allogenic bone marrow transplant (BMT) patients developed Stenotrophomonas maltophilia bacteremia on the hematology service at UCLA Medical Center (Los Angeles). Five of these patients had undergone transplantation during the same hospitalization that S. maltophilia bacteremia was detected (case patients). Compared with 7 concurrently hospitalized alloge...